A 16-Week Study to Learn About Ritlecitinib for Hidradenitis Suppurativa
Phase 2
240
about 1.4 years
18–75
4 sites in CA, IN, MI +1
What this study is about
This trial is testing a treatment called Ritlecitinib in adults with hidradenitis suppurativa (HS), a condition causing painful red skin lumps. Participants will be randomly assigned to receive either Ritlecitinib or a placebo pill, taking it daily at home for about 24 weeks. It involves regular clinic visits and symptom tracking via an eDiary.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Ritlecitinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ritlecitinib
oral (Oral Capsule)
Secondary: Absolute score and CFB in Hidradenitis Suppurativa Quality of Life (HiSQOL), CFB in Hidradenitis Suppurativa Symptom Daily Diary (HSSDD), CFB in skin pain NRS, at worst and on average, respectively, Incidence of treatment emergent adverse events (TEAE), adverse events (AE) and serious adverse events (SAE) leading to discontinuation, Percent CFB in skin pain NRS, at worst and on average, respectively, in participants with baseline skin pain NRS ≥3, Percent change from Baseline(CFB) in total AN count, Skin pain NRS30 (numeric rating scale) response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3, Skin pain NRS50 response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3.